Genetic variants associated with methotrexate-induced mucositis in cancer treatment: a systematic review and meta-analysis.
Ver/
Fecha
2021-03-29Autor
Maagdenberg, Hedy
Oosterom, Natanja
Zanen, Jolanda
Gemmati, Donato
Windsor, Rachael E.
Heil, Sandra G.
Esperón, Patricia
Jabeen, Shakila
Ruiz Argüelles, Guillermo J.
Zolk, Oliver
Hoerning, Susanne
Sleurs, Charlotte
Moreno Galván, Mónica
van den Heuvel-Eibrink, Marry M.
Maitland-van der Zee, Anke H.
Carleton, Bruce C.
Metadatos
Mostrar el registro completo del ítem
Critical Reviews in Oncology/Hematology 161 : (2021) // Article ID 103312
Resumen
Methotrexate (MTX), an important chemotherapeutic agent, is often accompanied with mucositis. The occurrence and severity are unpredictable and show large interindividual variability. In this study, we review and meta-analyze previously studied genetic variants in relation to MTX-induced mucositis. We conducted a systematic search in Medline and Embase. We included genetic association studies of MTX-induced mucositis in cancer patients. A meta-analysis was conducted for single nucleotide polymorphisms (SNPs) for which at least two studies found a statistically significant association. A total of 34 SNPs were associated with mucositis in at least one study of the 57 included studies. Two of the seven SNPs included in our meta-analysis were statistically significantly associated with mucositis: MTHFR c.677C > T (recessive, grade ≥3 vs grade 0–2, OR 2.53, 95 %CI [1.48–4.32], False Discovery Rate[FDR]-corrected p-value 0.011) and MTRR c.66A > G (overdominant, grade ≥1 vs grade 0, OR 2.08, 95 %CI [1.16–3.73], FDR-corrected p-value 0.042).